Is double-seropositive myasthenia gravis a distinct subtype?

Affiliations

¹ DM Neurology Resident, Institute of Human Behaviour and Allied Sciences, Delhi, India. vaibhavseth1209@mail.com.
² Head of the Department, Institute of Human Behaviour and Allied Sciences, Delhi, India.
³ DM Neurology Resident, Institute of Human Behaviour and Allied Sciences, Delhi, India.

Vaibhav Seth et al. Acta Neurol Belg. 2023 Feb.

. 2023 Feb;123(1):251-252.

doi: 10.1007/s13760-021-01759-2. Epub 2021 Jul 26.

¹ DM Neurology Resident, Institute of Human Behaviour and Allied Sciences, Delhi, India. vaibhavseth1209@mail.com.
² Head of the Department, Institute of Human Behaviour and Allied Sciences, Delhi, India.
³ DM Neurology Resident, Institute of Human Behaviour and Allied Sciences, Delhi, India.

No abstract available

References

1. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475–490. https://doi.org/10.1016/S1474-4422(09)70063-8 - DOI - PubMed - PMC
1. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60(12):1978–1980. https://doi.org/10.1212/01.wnl.0000065882.63904.53 - DOI - PubMed
1. Zhang J, Chen Y, Chen J, Huang X, Wang H, Li Y, Liu W, Feng H (2021) AChRAb and MuSKAb double-seropositive myasthenia gravis: a distinct subtype Zhang? Neurol Sci 42(3):863–869. https://doi.org/10.1007/s10072-021-05042-3 - DOI - PubMed - PMC
1. Rodolico C, Bonanno C, Toscano A, Vita G (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:660. https://doi.org/10.3389/fneur.2020.00660 (Published 2020 Jul 23) - DOI - PubMed - PMC
1. Hehir MK, Hobson-Webb LD, Benatar M et al (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89(10):1069–1077. https://doi.org/10.1212/WNL.0000000000004341 - DOI - PubMed